INFINITY PHARMACEUTICALS, INC. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q2 2023.

Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10 Aug 2023

Quick Takeaways

  • INFINITY PHARMACEUTICALS, INC. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q2 2023.
  • Headline metric: Return On Equity 213%.

What Changed

  • Return On Equity YoY change: <span class="text-red-600">-192%</span>.
  • Most recent SEC facts end date: 03 Aug 2023.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2023-08-03) highlights Return On Equity 212.6%, Return On Assets -98.6%, and Operating Margin -1636.7%.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

59.9/100

Caution Confidence medium

Return On Equity

213%

Metric score 100.0/100

Return On Assets

-99%

Metric score 0.0/100

Financial Health

Current Ratio
1.65x
Debt to Equity
-2.52x

Strengths

Return On Equity, Current Ratio, and Revenues YoY

Watchpoints

Return On Assets, Operating Margin, and Debt-to-equity

Key metrics snapshot

Return On Equity

213%

YoY: -192%

Industry median: -43% (n=671)

View history

Return On Assets

-99%

YoY: +73%

Industry median: -48% (n=669)

View history

Operating Margin

-1637%

YoY: -22%

Industry median: -128% (n=298)

View history

Current Ratio

1.65x

YoY: -60%

Industry median: 3.39x (n=667)

View history

Debt-to-equity

-2.52x

YoY: -163%

Industry median: 0.28x (n=634)

View history

Revenues YoY

16%

YoY:

Industry median: 5% (n=103)

View history

NetIncomeLoss YoY

12%

YoY:

Industry median: -0.54% (n=641)

View history

Profitability

Metric Latest value YoY change
Return On Equity 213% -192%
Return On Assets -99% +73%
Operating Margin -1637% -22%

Financial Health

Metric Latest value YoY change
Current Ratio 1.65x -60%
Debt-to-equity -2.52x -163%

Growth

Metric Latest value YoY change
Revenues YoY 16%
NetIncomeLoss YoY 12%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 90,761,081 +1.7%
Common Stock, Shares, Outstanding 90,761,081 +1.7%
Common Stock, Value, Issued $90,000 +1.1%
Weighted Average Number of Shares Outstanding, Basic 89,885,492 +0.81%
Weighted Average Number of Shares Outstanding, Diluted 89,885,492 +0.81%

Additional Metrics

Metric Latest value YoY change
Revenue from Contract with Customer, Excluding Assessed Tax $2,569,000 +16%
Research and Development Expense $27,076,000 -19%
General and Administrative Expense $15,990,000 +12%
Operating Income (Loss) $42,046,000 +9.9%
Nonoperating Income (Expense) $1,098,000 +412%
Earnings Per Share, Basic 0 +12%
Earnings Per Share, Diluted 0 +12%
Cash and Cash Equivalents, at Carrying Value $17,746,000 -61%
Other Assets, Current $377,000 -3.1%
Assets, Current $19,908,000 -67%
Property, Plant and Equipment, Net $589,000 -42%
Operating Lease, Right-of-Use Asset $493,000 -44%
Other Assets, Noncurrent $84,000 -55%
Assets $21,232,000 -66%
Accounts Payable, Current $1,502,000 -17%
Employee-related Liabilities, Current $1,224,000 -47%
Liabilities, Current $12,064,000 -16%
Operating Lease, Liability, Noncurrent $0 -100%
Other Liabilities, Noncurrent $0 -100%
Liabilities $58,638,000 -6.9%
Retained Earnings (Accumulated Deficit) $876,953,000 -4.9%
Stockholders' Equity Attributable to Parent $37,406,000 -3279%
Liabilities and Equity $21,232,000 -66%
Common Stock, Shares Authorized 200,000,000 0%
Common Stock, Shares, Issued 90,761,081 +1.7%
Common Stock, Par or Stated Value Per Share 0 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17,904,000 -61%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $40,930,000 +13%
Lessee, Operating Lease, Liability, to be Paid $700,000 -46%
Operating Lease, Liability, Current $633,000 +14%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Authorized 1,000,000 0%
Preferred Stock, Shares Outstanding 0
Share-based Payment Arrangement, Expense $4,569,000 +44%
Preferred Stock, Par or Stated Value Per Share 0 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY